Bend Research Adds to Oral and Inhalation Capabilities - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Bend Research Adds to Oral and Inhalation Capabilities

Bend Research, part of Capsugel’s Dosage Form Solutions business unit, has added Capsugel’s Xcelodose powder-filling technology. The microdosing technology will help develop Bend Research’s recently announced Rapid Advancement of Preclinical Compounds initiative.

The Xcelodose 600S powder microdosing system enables the dispensing of dose weights as low as 100 micrograms, without excipients or bulking agents. The technology is used to prepare products for clinical trials and small-scale production.
The Xcelodose technology will have specific applications in Bend Research’s oral and inhalation product development.

Source: Bend Research


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here